Across TCGA pan-cancer cohorts, FAM174C mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM174C data layer compared with 25 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM174C mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM174C expression acts as an unfavorable survival marker.
LUAD are the cancer types where FAM174C mass-spec protein most reproducibly stratifies survival.